EKEkaterina S. Klyachina

Ekaterina S. Klyachina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ekaterina S. Klyachina has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Place of Antidepressants and Anxiolytics in the Treatment of Patients with Arterial Hypertension in Modern Living Conditions

    by Ekaterina S. Klyachina, Olga G. Smolenskaya, Svetlana S. Vedenskaya

    Introduction. Recently cardiac diseases depression, and anxiety have shown high levels of comorbidity. Over the past 5 years, the COVID-19 pandemic has also made an important contribution to the development of anxiety and depression, which has had a significant impact on the prognosis and quality of life of patients. The aim of the study is to evaluate the indicators of anxiety and depression in patients with hypertension who have had pneumonia caused by COVID-19 who do not reach the target blood pressure values, as well as to study the effect of psychopharmacotherapy in this category of patients during 3 months of follow-up. Methods. A prospective study of patients with COVID-19 who had uncontrolled hypertension and increased anxiety/depression was conducted. Patients from 2 groups were compared: group 1 — patients who took only antihypertensive therapy (n = 23), group 2 — patients who used psychopharmacotherapy in addition to antihypertensive therapy (n = 21). Results. Reactive anxiety was registered in all patients from 2 groups. After 3 months, there was a statistically significant decrease in the high level of reactive anxiety in patients using psychopharmacotherapy. There were no significant changes in the results of reactive anxiety in patients from the comparison group. Depression was detected less frequently than anxiety disorders: group 1 — 3/23 (13,04 %) people (only mild); group 2 — 6/21 (28,57 %) patients (mild — 4/21 (19,05 %); severe — 2 (9,52 %)), p = 0,203. Antidepressants were prescribed only 2 patients with a pronounced level of depression at the initial examination. By the 3rd month of using these drugs, the patients’ depression levels had decreased to moderate. By the 3rd month of follow-up, 8/23 (34,78%) patients in group 1 and 18/21 (85,71 %) patients in group 2 reached the target BP figures, p < 0,001. Conclusion. Patients with increased anxiety and depression who have uncontrolled hypertension should add psychopharmacotherapy to the main antihypertensive therapy in order to stabilize blood pressure and reduce the level of psychoemotional stress.

  • Open Access

    Registry as a tool for monitoring effectiveness of immunobiological therapy for severe asthma in real clinical practice

    by V. V. Naumova, D. V. Kiseleva, K. A. Zykov, Е. К. Beltyukov, E. S. Klyachina, I. O. Nikiforova, P. A. Suvorkov

    Registry is a unique and universal mechanism for group and individual approaches to managing patients, including those with severe asthma (SA) who require targeted therapy.The aim is to evaluate the clinical and organizational potential of the SA patient registry as a tool for group and individual approaches to patient management, as a way to describe and systematize the signs of bronchial asthma, comorbid diseases, and monitoring immunobiological therapy (using anti-IgE therapy as an example) in patients with SA in Sverdlovsk region.Methods. The subject of the study was the Territorial Registry of Patients with SA of the Sverdlovsk region. The registry effectiveness was assessed based on the clinical and organizational indicators, including monitoring the effectiveness of 3-year anti-IgE therapy in patients with SA with an allergic component.Results. From 2016 to 2023, both inclusive, 198 patients with SA were entered into the registry. Analysis of the registry data allowed us to develop a scheme for SA phenotyping and selecting the 1st and 2nd line targeted drugs and a scheme for phenotyping and selecting a targeted drug for T2 inflammatory nasal diseases. Over 3 years of anti-IgE therapy with omalizumab, the ACT test increased from 9.00 to 19.50 points, the proportion of patients with partial and good asthma control increased by 13.89 times, the frequency of exacerbations decreased by 71.43%, FEV1 increased by 17.91%, and the proportion of patients requiring systemic corticosteroids decreased by 83.32%.Conclusion. The registry of SA patients has high clinical and organizational potential to describe and systematize the signs of bronchial asthma, comorbid diseases, and monitor the effectiveness and safety of immunobiological therapy. The 3-year anti-IgE therapy demonstrates statistically significant effectiveness in patients with SA with an allergic component.

  • Open Access

    Coagulation hemostasis disorders and elevated lipoprotein (a) levels in patients with arterial hypertension and multifocal atherosclerosis

    by S. S. Vedenskaya, O. G. Smolenskaya, E. K. Beltyukov, V. G. Grachev, E. S. Klyachina, A. D. Kovaleva

    Introduction. Hemostatic disorders may act as additional risk factors in patients with arterial hypertension (AH) and multifocal atherosclerotic lesion (MFAL). Elevated lipoprotein (a) (Lp(a)) levels may exacerbate procoagulant shifts.Aim. To identify disorders in the coagulation link of hemostasis in patients with AH and MFAL, depending on the level of Lp(a).Materials and methods. The study included 219 patients with hypertension and MFAL, median age 59 (53; 66) years, of which 110 patients with stage I–II controlled hypertension (group 1) and 109 patients with stage III controlled hypertension with a history of ischemic stroke. Depending on the level of Lp(a), patients in each group were divided into 2 subgroups with Lp(a) levels < 50 mg/dl and with Lp(a) levels above 50 mg/dl. Patients of both groups received antihypertensive, lipid-lowering, antiplatelet therapy and had comparable values of blood pressure and lipid spectrum.Results. In group 2 patients, procoagulant shifts were significantly more often recorded, despite the constant use of antiplatelet therapy. Violations of hemostasis parameters depending on the level of Lp(a) were observed in subgroups 1b and 2b. According to the results of multiple a posteriori comparisons, the most significant hypercoagulation changes were observed in patients with stroke, as well as with Lp(a) levels > 50 mg/dl.Conclusions. Thus, in some patients with hypertension and MFAL, despite taking antihypertensive, lipid-lowering and antiplatelet therapy, coagulation hemostasis disorders may occur. Elevated Lp(a) levels are combined with more pronounced hemostatic disorders, especially in the presence of a previous stroke. Intensification of antithrombotic therapy may be considered in such patients to prevent cardiovascular complications.

  • Open Access

    Pro‑coagulant Considerations in Patients with Arterial Hypertension and Multifocal Atherosclerosis

    by S. S. Vedenskaya, O. G. Smolenskaya, V. G. Grachev, E. S. Klyachina, K. V. Shirobokova

    The aim of the work to determine the features of hemostasis and blood rheology in patients with arterial hypertension (HTN) and multifocal atherosclerosis (MFA).Materials and methods. The study enrolled male and female patients aged from 40 to 70 years, including 59 patients with controlled stage I–II hypertension and multifocal vascular lesions (Group 1) and 42 patients with controlled stage III hypertension, who have suffered an ischemic stroke and have multifocal vascular lesions (Group 2). A test using the Thrombodynamics analyser system T-2 (GemaKor, LLC, Moscow, Russia) was performed to detect the impairment of hemostasis.Results. Patients with HTN and MFA have an impaired coagulation hemostasis system (an increase in the initial and stationary clot growth rate and the size of the clot, as well as the presence of spontaneous clots), which leads to a high residual risk of cerebral complications, despite BP lowering to target figures and control of lipid profile.Discussion. Elevated blood pressure in patients with MFA leads to endothelial dysfunction, which is accompanied by activation of coagulation and fibrinolysis pathways. These changes lead to a violation of microcirculatory hemostasis in the brain, the development and progression of cerebral ischemia, and subsequently the occurrence of stroke, both the first and repeated.Conclusion. An important result of this study is the first registered change in the coagulation link of hemostasis in patients with HTN and MFA aged from 40 to 70 years, which can be considered an additional criterion for stroke prediction.

  • Open Access

    Clinical and allergological characteristics of patients with severe bronchial asthma in the regional registry and phenotyping principles for the targeted therapy choice

    by V. V. Naumova, E. K. Beltyukov, O. P. Kovtun, O. G. Smolenskaya, G. A. Bykova, E. S. Klyachina

    Introduction. Severe asthma targeted therapy effectiveness depends on precise targeting of the selected drug to the key link in pathogenesis. Therefore, severe asthma phenotyping in real clinical practice is relevant.Aim. To determine main clinical and allergological characteristics of patients with severe asthma and to establish important phenotyping signs determined choice of a targeted drug for severe asthma treatment.Materials and methods. The prospective and retrospective study involved patients (n = 198) of the Sverdlovsk region registry receiving targeted therapy of severe asthma. Considering clinical and allergological picture, allergic, non-allergic eosinophilic and mixed severe asthma phenotypes were identified. Clinical and laboratory characteristics of phenotypes were described. A phenotyping algorithm was developed.Results. In the register of patients (n = 198) with severe asthma, non-allergic eosinophilic asthma was 46.5%, allergic – 34.8%, mixed – 18.7%. Significant signs for phenotyping were identified: age of asthma onset, proven allergy, Phadiatop ImmunoCAP level and blood eosinophils on baseline, concomitant allergic rhinitis, chronic rhinosinusitis with nasal polyps and hyper-sensitivity to NSAIDs. The main signs of allergic severe asthma determined: early onset, proven allergy and a positive result of Phadiatop ImmunoCAP (the probability of allergic phenotype increases with Phadiatop ≥ 1.53 PAU/l). Signs of non-allergic eosinophilic asthma were eosinophilia ≥ 150 cells/µl, absence of allergy, concomitant chronic rhinosinusitis with nasal polyps and hypersensitivity to NSAIDs, late onset (after 30 years). Signs were identified for mixed asthma: presence of proven allergy or latent sensitization in combination with high level of Phadiatop ImmunoCAP, late onset, eosinophilia ≥ 300 cells/µl, chronic rhinosinusitis with nasal polyps, hypersensitivity NSAIDs.Conclusions. The algorithm for severe asthma phenotyping based on the isolation of eosinophilia of allergic and non-allergic origin is proposed. Severe asthma phenotyping, which can be carried out in real clinical practice, should facilitate the selection of an initial targeted drug.


  • Open Access

    Hemostasis parameters in patients with arterial hypertension, multifocal atherosclerosis and risk factors

    by S. S. Vedenskaya, O. G. Smolenskaya, V. G. Grachev, E. S. Klyachina, I. N. Kupriyanova, V. A. Vedensky

    Aim. To determine the features of hemostasis system disorders and the possibility of their correction in patients with arterial hypertension (AH) and multifocal atherosclerotic lesions (MFA) with risk factors indicated.Materials and methods. The study included 135 patients (mean age 53.7 ± 7.76 years), including 80 patients with controlled AH stage and II (group 1) and 55 patients with controlled AH stage III who had ischemic stroke (group 2). Among all patients studied, 33 patients (24.4 %) were smokers. All 135 patients received comparable antihypertensive, antiplatelettherapy (acetylsalicylic acid at a dose of 100 mg/day), had MFA and target lipid spectrum values.Results. Procoagulant shifts are noted already in patients with AH stage I and II, especially in the presence of smoking. Such indices of global thrombodynamics test as initial clot growth rate, average clot growth rate, clot size significantly exceed the reference values and indicate high prothrombogenic potential in patient with AH and MFA. Prescription of dual antiplatelet therapy allows normalization of identified disorders. Presence of risk factors (smoking) aggravates existing hemostasis disorders in patients with AH and MFA.Conclusion. Smoking cessation, optimization of risk factors and complex antihypertensive, hypolipidemic and antithrombotic therapy are the basis of treatment of patients with AH and MFA and can be considered as priority measures to reduce morbidity and mortality in this patient population.


  • Open Access

    Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part II. Analysis of patients discharged from the infectious diseases hospital

    by E. S. Klyachina, O. G. Smolenskaya, A. G. Makarochkin, S. S. Vedenskaya

    Introduction. Currently, there is evidence of a beneficial effect of statins among patients in the acute period of COVID-19. Much less is known about the effect of taking statins on the health of patients in the immediate period after recovery from COVID-19, especially in patients with concomitant cardiological pathology.The aim of the study was to evaluate the relationship of regular statin intake with the development of cardiovascular events in discharged patients with cardiovascular pathology during the acute period of COVID-19 and within 3 months after discharge from the infectious diseases hospital.Materials and methods A retrospective, cohort, observational study of patients who have had COVID-19 and have a history (before COVID-19) of cardiovascular pathologies, in which regular intake of hypolipidemic drugs is indicated, was conducted. Telephone and face-to-face visits were conducted with patients discharged from the infectious diseases hospital after 3 months.Results During the first three months after discharge from the infectious diseases hospital, 9 (21,95 %) new cardiovascular events were registered in patients not taking statins. In the subgroup of patients taking statins, 1 (3,03 %) cardiovascular event was registered. The chances of developing cardiovascular events in patients in the subgroup of patients not taking statins were 9 times higher than with regular administration (OR 0,11; 95% CI: 0,01–0,92), p = 0,036.Discussion The positive effect of taking statins observed in discharged patients after COVID-19 may be due to their additional pleiotropic effects.Conclusion The use of statins in patients with cardiovascular pathology was associated with a significant decrease in cardiovascular events within 3 months after discharge from the infectious diseases hospital.

  • Open Access

    Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part 1. Analysis of patients with fatal outcome during hospitalization

    by E. S. Klyachina, O. G. Smolenskaya, A. G. Makarochkin, S. S. Vedenskaya

    Introduction. Statins have a large number of pleiotropic effects, due to which they can be effective in cardiovascular complications of COVID-19. The aim of the study was to evaluate the relationship of regular statin intake with death and the development of new cardiovascular events in patients with cardiovascular pathology in the acute period of COVID-19. Materials and methods. A retrospective cohort study of patients diagnosed with COVID-19 with a history (before COVID-19) of cardiovascular pathologies, in which regular intake of lipid-lowering drugs is indicated, was conducted. Results. The study included 131 patients: 54 (41,22 %) people with a fatal outcome in the hospital; 77 (58,78 %) patients discharged from the infectious diseases hospital. During the period of hospitalization, 9 (16,67 %) cardiovascular events were documented in patients with a fatal outcome, more often in patients not taking statins, p = 0,399. The chance of death among hospitalized patients with COVID-19 with concomitant cardiovascular pathology is 2,62 times lower in patients taking statins, compared with patients who do not use these drugs for the treatment of cardiovascular diseases (OR 0,381; 95 % CI: 0,17–0,84), the differences are statistically significant (p = 0,015). Discussion. The beneficial effect of long-term statin intake observed in the acute period of COVID-19 is probably due to their additional protective effects: anti-inflammatory, antithrombotic, immunomodulatory and reducing endothelial dysfunction. Conclusions. Among patients with cardiovascular diseases hospitalized for COVID-19, only 1/3 takes the necessary lipid-lowering therapy. The use of statins before admission to the hospital and during treatment significantly reduces deaths in patients with cardiovascular pathology.


  • The risk of cardiac and cerebrovascular complications in patients with concomitant cardiovascular diseases who have had COVID-19

    by E. S. Klyachina, O. G. Smolenskaya

    During the pandemic caused by the SARS-CoV-2 virus, patients with cardiovascular diseases (CVD), which are often found in the population, are a special risk group. Cardiovascular complications after COVID-19 can occur at diff erent periods of the disease. This research describes cardiovascular complications in patients after recovery.The aim of the study was to identify the incidence of new CVD and complications of existing cardiac pathology in patients who recovered from COVID-19.Material and methods. A retrospective, observational study including 370 patients was conducted. All patients underwent telephone consultations within 6 months after the infectious diseases hospital discharge. When new CVDs, complications or anabasis were identifi ed, follow-up visits were initiated.Results. Among 370 patients under the study, concomitant CVD was registered in 249 (67.29%) people, 121 (32.71%) patients had no case history of cardiovascular pathology. In patients with concomitant CVD during the fi rst 6 months after the infectious diseases hospital discharge, 25 (10.04%) new cardiovascular events were registered, which is signifi cantly more frequent than in patients without case history of CVD (n = 1; 0.83%). The number of events described above was more often observed in the fi rst 3 months after discharge, which is statistically signifi cant (p ˂ 0.05). BP destabilization was most often observed (n = 67; 27.2%) as anabasis, which may be associated with an increased level of anxiety in patients. It was also noted that new CVDs, as well as anabasis, developed because of the timely specialized cardiological medical care absence, which probably led to undesirable events due to inability to correct CVD risk factors in time.Conclusions. In patients with concomitant CVD, who have had COVID-19, in contrast to patients without case history of CVD, the risk of developing new cardiovascular events is signifi cantly higher. Patients with CVD deserve the closest attention during the fi rst 3 months after discharge from the infectious diseases hospital.